Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ceramide nanoliposome (PendreaBio)
- Development stage
- Unknown
- Lead developer
- PendreaBio
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Ceramide nanoliposome is a **nanoliposomal formulation of C6-ceramide**, a sphingolipid metabolite with established pro-apoptotic and tumor suppressor activity. Its mechanism of action centers on **deactivating oncogenic signaling pathways** (such as AKT, ERK, and STAT3) and promoting cancer cell death via apoptosis, necrosis, and necroptosis. By encapsulating ceramide within a nanoliposome, the formulation increases the bioavailability and stability of ceramide, overcomes membrane permeability limitations, enables accumulation in tumor cells, and minimizes toxicity to non-cancerous tissues. Preclinical research and early-phase clinical studies have demonstrated single-agent anticancer activity, synergy with chemotherapy, immunotherapy, and targeted agents, and preliminary safety in solid tumors. The formulation is developed primarily for advanced solid tumors, liver cancer, pancreatic cancer, and has orphan drug status for several indications[1][4][5][9][3][7].
- Brand names
- Ceraxa
- Other names
- Ceramide NanoLiposomeCeraxa #1Ceraxa #2nanoliposomal ceramideceramide nanoliposomal
02
Targets
MAPK3 (Mitogen-activated protein kinase 1)MLKL (Mixed lineage kinase domain-like protein)AKT (RAC-alpha serine/threonine-protein kinase)PP1 (Protein phosphatase 1)PP2A (Protein phosphatase 2A)STAT3 (Signal Transducer and Activator of Transcription 3)
Beyond the preview
Go deeper on ceramide nanoliposome (PendreaBio).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ceramide nanoliposome (PendreaBio).